Target intelligence / Profile preview

SARS-CoV-2 peptide-Major Histocompatibility Complex class I (SARS-CoV-2 pMHC-I)

Target
SARS-CoV-2 pMHC-I
Molecular classification
Antigen-MHC complex, Protein complex
01

Overview

SARS-CoV-2 peptide-Major Histocompatibility Complex class I (pMHC-I) refers to the molecular assembly of short viral peptide fragments (epitopes) bound to human leukocyte antigen (HLA) class I molecules on the surface of infected cells (Grifoni et al., 2020, Cell). These epitopes, typically 8 to 11 amino acids in length, are derived from the proteasomal degradation of SARS-CoV-2 proteins such as Spike (S), Nucleocapsid (N), and various non-structural proteins (Sette & Crotty, 2021, Cell). The primary biological function of this complex is to present intracellular viral antigens to the adaptive immune system, specifically serving as the ligand for the T-cell receptor (TCR) on CD8+ cytotoxic T lymphocytes (CTLs) (Le Bert et al., 2020, Nature). Upon recognition of the pMHC-I complex, CTLs are activated to eliminate the infected cell through the secretion of cytotoxic granules containing perforin and granzymes, thereby limiting viral spread. In clinical practice, these complexes are the fundamental targets of COVID-19 vaccines, which aim to prime the immune system to recognize these epitopes upon natural infection (Sahin et al., 2020, Nature). They are also the focus of emerging therapeutic strategies, including adoptive T-cell transfer and TCR-engineered T-cell (TCR-T) therapies, which seek to enhance the cellular immune response in immunocompromised or severely ill patients (Panagioti et al., 2021, Frontiers in Immunology). However, the effectiveness of targeting these complexes is influenced by HLA polymorphism across human populations and the potential for viral mutations to alter epitope sequences, leading to immune escape (Harvey et al., 2021, Nature Reviews Microbiology).

Other names
SARS-CoV-2 CD8+ T-cell epitopesSARS-CoV-2 HLA class I complexesCOVID-19 CTL epitopesSARS-CoV-2 MHC-I peptide complexSARS-CoV-2–derived CTL epitopes presented on human MHC class I molecules
02

Mechanism of action

Presentation of viral peptides to CD8+ T cells to induce targeted lysis of infected cells and establish immunological memory.

03

Biological functions

Antigen presentationT cell activationImmune responseCellular immunity
04

Disease associations

InfectionCOVID-19
05

Safety considerations

Viral escape mutations (immune evasion)HLA restriction (limited population coverage)Potential for cross-reactivity with self-antigensCytokine release syndrome in T-cell therapies
06

Interacting drugs

BNT162b2 (Tozinameran)

4 more in the full profile.

07

Biomarkers

HLA-A*02:01 (and other HLA alleles)Interferon-gamma (IFN-γ) ELISpotPeptide-MHC tetramer bindingCD8+ T-cell frequency

Beyond the preview

Go deeper on SARS-CoV-2 peptide-Major Histocompatibility Complex class I (SARS-CoV-2 pMHC-I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 peptide-Major Histocompatibility Complex class I (SARS-CoV-2 pMHC-I).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call